IL6 and cancer: hsCRP and IL6 were reduced by 52.4% and 30.9% with baseline hsCRP 4.2 mg/dl. no effect on lipid profile.Increased risk of neutropenia and thrombocytopenia.Reduced risk of arthritis, gout, and cancer-related mortality.